West Pharmaceutical Services, Inc. (NYSE:WST) named one of the 14 Best Dividend Growth Stocks for 2026. KeyBanc predicts ongoing demand for injectable GLP-1s, with limited risk to oral weight loss drugs. Oral GLP-1 adoption likely to remain capped, with injectable formats driving growth. WST raised profit forecast after strong Q3 results, drug components now 47% of revenue.

Read more at Yahoo Finance: KeyBanc Sees Injectable GLP-1s Driving Ongoing Demand for WST